Researchers at the University of Texas MD Anderson Cancer Center have developed a novel antibody-toxin conjugate (ATC) designed to stimulate immune-mediated eradication of tumors. According to preclinical results published in Nature Cancer, the new approach combines the benefits of more well-known antibody-drug conjugates (ADCs) with those of immunotherapies.
Leave A Comment